Lori Wirth, MD, a medical oncologist, reviews the case of a 64-year-old woman with differentiated thyroid cancer (DTC).
A 64-Year-Old Woman with DTC
A leading expert on head and neck oncology provides her initial impressions on the case of a 64-year-old woman with differentiated thyroid cancer.
A medical oncologist provides a comprehensive overview of the current treatment options for patients with advanced RAI-refractory DTC and reviews clinical trial data on sorafenib and lenvatinib.
Lori Wirth, MD, discusses the safety profiles of sorafenib and lenvatinib and provides clinical insights on managing or mitigating adverse effects.
An overview of the standard of care treatment for patients with advanced radioiodine-refractory differentiated thyroid cancer.
A medical oncologist reviews real-world data on older patients with RAI-refractory DTC and provides her thoughts on treating this patient population.
Lori Wirth, MD, discusses molecular testing practices for patients with advanced RAI-refractory differentiated thyroid cancer.
An expert on thyroid cancer provides insights on treating patients with advanced RAI-refractory DTC who harbor BRAFV600E mutations.
Lori Wirth, MD, discusses second-line treatment in relation to the patient case, and concludes the discussion with a look at emerging treatment options and the future of treating advanced RAI-refractory DTC.